Lorus recruits first patient in anticancer drug Phase I trial
The Phase I study is expected to recruit 22-37 patients with advanced or metastatic solid tumors for which no effective therapy is currently available, or whose cancer has
WuXi XDC Cayman has signed an agreement to provide Ona Therapeutics with an exclusive global licence to its WuXiTecan-2 payload-linker technology platform for the development of an antibody-drug conjugate (ADC) candidate.
Calcitonin is a drug indicated for the treatment of postmenopausal osteoporosis, hypercalcemia, and Paget’s disease, and is commercially available in subcutaneous, intramuscular and nasal routes. The open-label, single-dose,